eTheRNA immunotherapies NV, a clinical-stage Belgian company developing mRNA based immunotherapies for the treatment of cancer and IAG, a bio-pharma expert imaging company announced today a a collaboration aimed at facilitating the clinical evaluation of immuno-therapies based on eTheRNA’s proprietary mRNA-based TriMix platform with the use of IAG’s cloud based software DYNAMIKA.
Компания «Интеллоджик» информирует о привлечении раунда А инвестиций для развития платформы искусственного интеллекта в области здравоохранения Botkin.AI.
IAG, Image Analysis Group, a strategic imaging partner for bio-pharma companies, announced they have entered into an collaboration with IMV’s to validate how advanced imaging techniques can help assess the tumor microenvironment in a subset of patients in IMV’s ongoing phase 2 basket trial, which is evaluating DPX-Survivac in combination with pembrolizumab in multiple solid tumor indications.
Robust financing to support advancement of Immusoft’s novel B cell platform
Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I
